Evidence map›Paper›PMID 27589857›Full record

ArticleEuropean biophysics journal : EBJ2017

Oligomerization of the antimicrobial peptide Protegrin-5 in a membrane-mimicking environment. Structural studies by high-resolution NMR spectroscopy.

Konstantin S Usachev, Olga A Kolosova, Evelina A Klochkova, Aidar R Yulmetov, Albert V Aganov, Vladimir V Klochkov

Abstract read
PubMed Publisher
In one paragraph

Article in European biophysics journal : EBJ, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. SAAP-148 Oligomerizes into a Hexamer Forming a Hydrophobic Inner Core.Chembiochem : a European journal of chemical biology · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Pharmaceutics · 2018
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Konstantin S UsachevKazan Federal University, 18 Kremlevskaya St., 420008, Kazan, Russian Federation.
Olga A KolosovaKazan Federal University, 18 Kremlevskaya St., 420008, Kazan, Russian Federation.
Evelina A KlochkovaKazan Federal University, 18 Kremlevskaya St., 420008, Kazan, Russian Federation.
Aidar R YulmetovKazan Federal University, 18 Kremlevskaya St., 420008, Kazan, Russian Federation.
Albert V AganovKazan Federal University, 18 Kremlevskaya St., 420008, Kazan, Russian Federation.
Vladimir V KlochkovKazan Federal University, 18 Kremlevskaya St., 420008, Kazan, Russian Federation. vladimir.klochkov@kpfu.ru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protegrin pore formation is believed to occur in a stepwise fashion that begins with a nonspecific peptide interaction with the negatively charged bacterial cell walls via hydrophobic and positively charged amphipathic surfaces. There are five known nature protegrins (PG1-PG5), and early studies of PG-1 (PDB ID:1PG1) shown that it could form antiparallel dimer in membrane mimicking environment which could be a first step for further oligomeric membrane pore formation. Later, we solved PG-2 (PDB ID:2MUH) and PG-3 (PDB ID:2MZ6) structures in the same environment and for PG-3 observed a strong d

Indexed as

Membranes, ArtificialProtein MultimerizationAmino Acid SequenceAntimicrobial Cationic PeptidesCell MembraneHydrophobic and Hydrophilic InteractionsMagnetic Resonance SpectroscopyMicellesModels, MolecularProtein Conformation, beta-StrandAntimicrobial Cationic PeptidesMembranes, ArtificialMicellesprotegrin-5AntibioticAntimicrobial peptideNMRPoreProtegrinStructure

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.